ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.
Essam Ghazaly(Queen Mary University of London), Sarah P. Blagden(Churchill Hospital), Hani Gabra(Royal Children's Hospital), Nagy Habib(Hammersmith Hospital), Magdalena Ślusarczyk(Cardiff University), Harpreet Wasan(Peter MacCallum Cancer Centre), John G. Gribben(Queen Mary University of London), Christopher McGuigan(University College Dublin), Oluwadunni E. Emiloju(Imperial College London), T.G. Hopkins(Imperial College London), Robert Leonard(National Cancer Centre Japan), Simon Joel(Queen Mary University of London), Tariq Mohammad(Imperial College London), Chara Stavraka(King's College London)
Cited by 8
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k